An interventional study of Photobiomodulation in Mucositis Oral, Head and Neck Cancer and Radiation Dermatitis, sponsored by Ottawa Hospital Research Institute. Active, not recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Ottawa Hospital Research Institute · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Radiotherapy for head and neck cancer can cause severe mucositis (ulcers in the mouth) and pain. Photobiomodulation (Light therapy) will be used before and during radiotherapy to try to reduce the occurence and severity of mucositis in patients treated with radiotherapy for head and neck cancer
Previous studies in head and neck cancer patients have shown that photobiomodulation (light therapy) can prevent mucositis. There are currently no centers in Canada using this technique in routine practice, but this is recommended in International guidelines and widely used in Europe. The investigators therefore wish to implement this technique in Ottawa under the umbrella of a clinical trial to insure its safety and efficacy in a Canadian context.
Introduction: Radiotherapy for head and neck cancer can cause severe mucositis (ulcers in the mouth) and pain. Photobiomodulation (Light therapy) will be used before and during radiotherapy to try to reduce the occurence and severity of mucositis in patients treated with radiotherapy for head and neck cancer
Rationale: Previous studies in head and neck cancer patients have shown that photobiomodulation (light therapy) can prevent mucositis. There are currently no centers in Canada using this technique in routine practice, but this is recommended in International guidelines and widely used in Europe. The investigators therefore wish to implement this technique in Ottawa under the umbrella of a clinical trial to insure its safety and efficacy in a Canadian context.
Purpose/Objectives: Primary Objective Primary Objective
Secondary Objectives
To determine the following during radiotherapy and for 24 months post-treatment
Study design/methodology:
This is single arm prospective cohort study of a single intervention (photobiomodulation) in patients with head and neck cancer for the prevention of oral mucositis.
Outcomes will be the following:
Anticipated public/scientific benefit:
This study aims to study the use of Photobiomodulation treatments for prevention of oral mucositis. This is recommended in international guidelines but not used in routine practice in Canada. The benefit of this study is to allow implemetation of this technique in the Canadian context in a controlled and evaluated manner. This will hopefully then allow further study and wider implementation of this technique both in Ottawa and in Canada
307 studies on the registry are indexed under Stomatitis; 74 are open to participants now.
This study's planned enrollment of 25 is below the median of 60 across 277 interventional studies indexed under Stomatitis.
Browse Stomatitis studies →Ottawa Hospital Research Institute is the lead sponsor of 547 studies on the registry; 99 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Parameters: combined 633nm and 870 nm @1000mW * 1 Treatment pre radiotherapy * 3 treatments weekly during radiotherapy
Device: Photobiomodulation
Parameters: combined 633nm and 870 nm @1000mW * 1 Treatment 4J continuous prior to RT. (Within 14 days of RT start) * 3 treatments weekly during RT (6 J at 12 Hz, 80% duty cycle)
Rate of occurence of radiation mucositis
CTCAE version 2.0
Time frame: 7-14 days post radiotherapy
Rate of occurence of radiation mucositis
CTCAE version 2.0
Time frame: 1 month post radiotherapy
Rate of occurence of radiation mucositis
CTCAE version 2.0
Time frame: 3 months post radiotherapy
Rate of occurence of radiation mucositis
CTCAE version 2.0
Time frame: 6 months post radiotherapy
Rate of occurence of radiation mucositis
CTCAE version 2.0
Time frame: 12 months post radiotherapy
Rate of occurence of radiation mucositis
CTCAE version 2.0
Time frame: 24 months post radiotherapy
Brief Pain Inventory
Pain questionnaire
Time frame: 7-14 days post radiotherapy
Brief Pain Inventory
Pain questionnaire
Time frame: 1 month post radiotherapy
Brief Pain Inventory
Pain questionnaire
Time frame: 3 months post radiotherapy
Brief Pain Inventory
Pain questionnaire
Time frame: 6 months post radiotherapy
Brief Pain Inventory
Pain questionnaire
Time frame: 12 months post radiotherapy
Brief Pain Inventory
Pain questionnaire
Time frame: 24 months post radiotherapy
Functional Assessment of Cancer Therapy - Head & Neck (FACT-HN)
Swallowing related quality of life
Time frame: 7-14 days post-radiotherapy
Functional Assessment of Cancer Therapy - Head & Neck (FACT-HN)
Swallowing related quality of life
Time frame: 1 month post-radiotherapy
Functional Assessment of Cancer Therapy - Head & Neck (FACT-HN)
Swallowing related quality of life
Time frame: 3 months post-radiotherapy
Functional Assessment of Cancer Therapy - Head & Neck (FACT-HN)
Swallowing related quality of life
Time frame: 12 months post-radiotherapy
Functional Assessment of Cancer Therapy - Head & Neck (FACT-HN)
Swallowing related quality of life
Time frame: 24 months post-radiotherapy
EQ-5D
General Quality of life questionnaire
Time frame: 7-14 days post radiotherapy
EQ-5D
General Quality of life questionnaire
Time frame: 1 month post radiotherapy
EQ-5D
General Quality of life questionnaire
Time frame: 3 months post radiotherapy
EQ-5D
General Quality of life questionnaire
Time frame: 6 months post radiotherapy
EQ-5D
General Quality of life questionnaire
Time frame: 12 months post radiotherapy
EQ-5D
General Quality of life questionnaire
Time frame: 24 months post radiotherapy
Radiation dermatitis
CTCAE version 5.0
Time frame: 7-14 days post radiotherapy
Radiation dermatitis
CTCAE version 5.0
Time frame: 1 month post radiotherapy
Radiation dermatitis
CTCAE version 5.0
Time frame: 3 months post radiotherapy
Radiation dermatitis
CTCAE version 5.0
Time frame: 6 months post radiotherapy
Radiation dermatitis
CTCAE version 5.0
Time frame: 12 months post radiotherapy
Radiation dermatitis
CTCAE version 5.0
Time frame: 24 months post radiotherapy
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2021 (actual). Primary completion is estimated for Dec 2026, 66 months after the start.
Of 66 non-industry interventional studies with no phase under Stomatitis, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 57. This study's planned 66 months is above that.
Counting every sponsor, half of 74 studies reached it within 14 months; a quarter within 10 and three quarters within 32.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Dec 2025 → Dec 2026 and completion Dec 2025 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ottawa Hospital Research Institute →